Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizoti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takashi, Kanda, Shintaro, Fukushima, Toshirou, Noguchi, Takuro, Sekiguchi, Nodoka, Koizumi, Tomonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365006/
https://www.ncbi.nlm.nih.gov/pubmed/34184417
http://dx.doi.org/10.1111/1759-7714.14056
_version_ 1783738626239102976
author Kobayashi, Takashi
Kanda, Shintaro
Fukushima, Toshirou
Noguchi, Takuro
Sekiguchi, Nodoka
Koizumi, Tomonobu
author_facet Kobayashi, Takashi
Kanda, Shintaro
Fukushima, Toshirou
Noguchi, Takuro
Sekiguchi, Nodoka
Koizumi, Tomonobu
author_sort Kobayashi, Takashi
collection PubMed
description We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizotinib and alectinib resistance mutation. Subsequent therapy with the third‐generation ALK inhibitor lorlatinib, but not ceritinib, showed antitumor activity for 1 year. The uterus is an uncommon site for metastasis from lung cancer, and our case indicated that serial gene analysis could provide new information about ALK inhibitor resistance.
format Online
Article
Text
id pubmed-8365006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-83650062021-08-23 Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis Kobayashi, Takashi Kanda, Shintaro Fukushima, Toshirou Noguchi, Takuro Sekiguchi, Nodoka Koizumi, Tomonobu Thorac Cancer Case Reports We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizotinib and alectinib resistance mutation. Subsequent therapy with the third‐generation ALK inhibitor lorlatinib, but not ceritinib, showed antitumor activity for 1 year. The uterus is an uncommon site for metastasis from lung cancer, and our case indicated that serial gene analysis could provide new information about ALK inhibitor resistance. John Wiley & Sons Australia, Ltd 2021-06-28 2021-08 /pmc/articles/PMC8365006/ /pubmed/34184417 http://dx.doi.org/10.1111/1759-7714.14056 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Kobayashi, Takashi
Kanda, Shintaro
Fukushima, Toshirou
Noguchi, Takuro
Sekiguchi, Nodoka
Koizumi, Tomonobu
Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
title Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
title_full Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
title_fullStr Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
title_full_unstemmed Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
title_short Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
title_sort response to lorlatinib on a patient with alk‐rearranged non‐small cell lung cancer harboring 1151tins mutation with uterine metastasis
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365006/
https://www.ncbi.nlm.nih.gov/pubmed/34184417
http://dx.doi.org/10.1111/1759-7714.14056
work_keys_str_mv AT kobayashitakashi responsetolorlatinibonapatientwithalkrearrangednonsmallcelllungcancerharboring1151tinsmutationwithuterinemetastasis
AT kandashintaro responsetolorlatinibonapatientwithalkrearrangednonsmallcelllungcancerharboring1151tinsmutationwithuterinemetastasis
AT fukushimatoshirou responsetolorlatinibonapatientwithalkrearrangednonsmallcelllungcancerharboring1151tinsmutationwithuterinemetastasis
AT noguchitakuro responsetolorlatinibonapatientwithalkrearrangednonsmallcelllungcancerharboring1151tinsmutationwithuterinemetastasis
AT sekiguchinodoka responsetolorlatinibonapatientwithalkrearrangednonsmallcelllungcancerharboring1151tinsmutationwithuterinemetastasis
AT koizumitomonobu responsetolorlatinibonapatientwithalkrearrangednonsmallcelllungcancerharboring1151tinsmutationwithuterinemetastasis

Ejemplares similares